bdx-20220822
0000010795false00000107952022-08-222022-08-220000010795us-gaap:CommonStockMemberexch:XNYS2022-08-222022-08-220000010795exch:XNYSus-gaap:RedeemablePreferredStockMember2022-08-222022-08-220000010795bdx:Notes1.000dueDecember152022Memberexch:XNYS2022-08-222022-08-220000010795bdx:Notes1.900dueDecember152026Memberexch:XNYS2022-08-222022-08-220000010795bdx:Notes1.401dueMay242023Memberexch:XNYS2022-08-222022-08-220000010795exch:XNYSbdx:Notes3.020dueMay242025Member2022-08-222022-08-220000010795exch:XNYSbdx:Notes0.632dueJune42023Member2022-08-222022-08-220000010795bdx:Notes1.208dueJune42026Memberexch:XNYS2022-08-222022-08-220000010795exch:XNYSbdx:Notes1213DueFebruary122036Member2022-08-222022-08-220000010795exch:XNYSbdx:Notes0000DueAugust132023Member2022-08-222022-08-220000010795bdx:Notes0034DueAugust132025Memberexch:XNYS2022-08-222022-08-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) August 22, 2022
BECTON, DICKINSON AND COMPANY
(Exact Name of Registrant as Specified in Its Charter)
New Jersey
(State or Other Jurisdiction of Incorporation)
001-4802 22-0760120
(Commission File Number) (IRS Employer Identification No.)
  
1 Becton Drive, Franklin Lakes,
New Jersey
 07417-1880
(Address of Principal Executive Offices) (Zip Code)
(201) 
847-6800
 (Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:



Title of Each ClassTrading Symbol
Name of each exchange on
which registered
Common stock, par value $1.00BDXNew York Stock Exchange
Depositary Shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series BBDXBNew York Stock Exchange
1.000% Notes due December 15, 2022BDX22ANew York Stock Exchange
1.900% Notes due December 15, 2026BDX26New York Stock Exchange
1.401% Notes due May 24, 2023BDX23ANew York Stock Exchange
3.020% Notes due May 24, 2025BDX25New York Stock Exchange
0.632% Notes due June 4, 2023BDX/23ANew York Stock Exchange
1.208% Notes due June 4, 2026BDX/26ANew York Stock Exchange
1.213% Notes due February 12, 2036BDX/36New York Stock Exchange
0.000% Notes due August 13, 2023BDX23BNew York Stock Exchange
0.034% Notes due August 13, 2025BDX25ANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 25, 2022, Becton, Dickinson and Company ("BD") announced the appointment of two senior leaders to segment president roles.

Michael Garrison has been named BD's Executive Vice President and President, Medical Segment, and Richard Byrd has been named BD's Executive Vice President and President, Interventional Segment, both effective September 6, 2022.

In addition, on August 22, 2022, Simon Campion informed BD that he will depart BD on September 9, 2022 for an executive role in the health care industry. Mr. Campion joined BD through the acquisition of C.R. Bard, Inc. and most recently served as BD's Executive Vice President and President, Medical Segment.



ITEM 7.01. Regulation FD Disclosure.

On August 25, 2022, BD issued a press release relating to the matters described above in Item 5.02. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Item 7.01 shall neither be deemed "filed" for purposes of Section 18 on the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.




ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS    
Exhibit 99.1     Press release dated August 25, 2022, which is furnished pursuant to Item 7.01.

Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)
By:/s/ Gary DeFazio
 Gary DeFazio
 Senior Vice President and Corporate Secretary
Date: August 25, 2022

NEWS RELEASE FOR IMMEDIATE RELEASE BD Promotes Two Senior Executives to Segment Leadership Roles • Mike Garrison Named EVP and President, Medical segment • Rick Byrd Named EVP and President, Interventional segment FRANKLIN LAKES, N.J. (Aug. 25, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of two senior leaders to segment president roles. Michael (Mike) Garrison has been named executive vice president (EVP) and president of the Medical segment, and Richard (Rick) Byrd has been named executive vice president (EVP) and president of the Interventional segment, both effective Sept. 6. Garrison and Byrd will be responsible for the global operational, commercial and financial performance of the businesses that comprise their respective segments, including advancing the portfolio and innovation agenda aligned to the BD 2025 strategy. They will also be accountable for advancing the overall culture and high-performing talent landscape within their segments. They will be members of the BD Executive Leadership Team and report to Tom Polen, chairman, CEO and president of BD. In addition, BD announced that Simon Campion will depart the company on Sept. 9 for an executive role in the health care industry. Campion joined BD through the acquisition of Bard and led BD’s Interventional segment through the integration. He most recently served as president of the Medical segment. “Mike and Rick are highly effective leaders who have demonstrated strategic and operational excellence in their nearly two decades at BD,” said Tom Polen, chairman, CEO and president of BD. “Their focus on driving growth and meaningful outcomes has been critical as we pursue our BD 2025 strategy, and they are well-rounded, seasoned leaders with a track record of developing strong teams that deliver impactful results. Their broad experiences across multiple BD businesses and segments position them well for their new roles as we advance our growth agenda and build BD’s future. I would also like to thank Simon for his many contributions over his 14 years with Bard and BD.” Mike Garrison, EVP and president, Medical segment Garrison, 53, has served as worldwide president of BD Medication Management Solutions (MMS) since 2020, during which he advanced the innovation agenda including BD’s most recent acquisition of Parata Systems. Prior to that he was worldwide president of BD Surgery, where he helped integrate legacy Bard


 
and BD product platforms into an integrated Surgery offering and developed growth strategies for Advanced Repair and Reconstruction. He has also served as vice president and general manager of Worldwide Infusion Systems in MMS and held multiple senior roles across different business units across the company including vice president of Research and Development (R&D) for BD’s Medication and Procedural Solutions business unit. Before joining BD in 2005, Garrison worked at Edwards Lifesciences and Roche Diagnostics. Garrison earned a doctorate in Bioengineering from the University of Washington and Bachelor and Master of Science degrees in Biomedical and Electrical Engineering from Duke University. Rick Byrd, EVP and president, Interventional segment Byrd, 55, has served as worldwide president of Medication Delivery Solutions (MDS), BD’s largest business unit, since 2019, during which he drove high-impact category innovation through BD’s “One- Stick Hospital Stay” vision, which is transforming the in-patient experience by eliminating unnecessary needlesticks and accelerating growth with the acquisition of Velano Vascular. Previously, he served as worldwide president of Preanalytical Systems in BD Life Sciences, and vice president and general manager within BD Medical, where he led three global, multi-billion-dollar growth businesses within MDS. He also served in a number of R&D roles focused on innovation, including vice president of worldwide R&D within BD Medical. Byrd earned a master’s degree in Mechanical Engineering from Stevens Institute of Technology and a Bachelor of Science degree in Mechanical Engineering from Virginia Tech. # # # About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo. Contacts: Media: Investors: Troy Kirkpatrick Francesca DeMartino VP, Public Relations SVP, Head of Investor Relations 858.617.2361 201.847.5743 [email protected] [email protected]